FDA Inspection 1266180 — BioGenetics Corporation
The FDA completed an inspection of BioGenetics Corporation on Mar 14, 2025 in Mountainside, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 14, 2025
- Fiscal Year
- 2025
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Mountainside, NJ (United States)